Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
100 results about "Signaling proteins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Signaling proteins Proteins and other molecules serve one or more of several types of function in signaling networks: ... Messenger proteins carry the signal from one part of the cell to another. For example, messengers often carry signals from the cytosol to the nucleus.
Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
InactiveUS20050239134A1Increased proliferationPrevent proliferationPeptide/protein ingredientsAntiviralsDNA AptamersTgf β signalling
The present invention includes the selection and isolation of thioaptamers that target the signaling protein TGF-β1, compositions of such thioaptamers and the use of such thioaptamers to either block or enhance signal transduction of the TGF-β1 protein and thus function as, e.g., immunomodulatory agents. Thioaptamers may also be targeted alone or in combination with other thioaptamers against the ligand, the receptors, the ligand trap protein(s) and / or the co-receptors to modulate TGF-β signaling pathway.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Genetically modified human natural killer cell lines
ActiveUS8313943B2Increase rangeHelp studyDrug screeningImmunoglobulins against cell receptors/antigens/surface-determinantsFc(alpha) receptorFc receptor
The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
Owner:INST FOR CANCER RES
Superantibody synthesis and use in detection, prevention and treatment of disease
InactiveUS20090208418A1Facilitate its translocationFunction increaseUltrasonic/sonic/infrasonic diagnosticsSurgeryPurineApoptosis
Superantibodies having enhanced autophilic, catalytic, and / or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and / or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and / or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed.
Owner:INNEXUS BIOTECHNOLOGY INT LTD
System for detecting protease
InactiveUS7109293B2Suppress viral proliferationDecreased crop yieldCompound screeningApoptosis detectionProteinase activityProtease
Disclosed is a system for detecting a protease inside a cell. In one embodiment, the system includes a chimeric protein that comprises as covalently linked components: 1) at least one optionally masked signal protein; 2) at least one protease-specific cleavage site; and 3) at least one detectable amino acid sequence. The invention has a wide spectrum of applications including use in the detection of novel protease inhibitors inside cells and tissue.
Owner:AHRAM BIOSYST
Compound for targeted ubiquitinated degradation of Smad3
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Taste signaling in gastrointestinal cells
InactiveUS20050244810A1Increase synthesisReduce synthesisMicrobiological testing/measurementBiological testingDiabetes mellitusHuman cell
Disclosed are materials and methods relevant to taste transduction. Also disclosed are human gastrointestinal cells that comprise or are capable expressing endogenous taste signaling proteins. Also disclosed are human gastrointestinal cells that comprise or are capable of expressing endogenous taste signaling proteins as well as hormones, neurotransmitters or soluble mediators of the gastrointestinal tract that are involved in or affect metabolism, digestion and appetite. Also disclosed are the uses of these human cells or their membranes to study how compounds affect taste transduction and / or metabolism, digestion and appetite, including effects on satiety, emesis and diabetes.
Owner:MT SINAI SCHOOL OF MEDICINE +1
Small molecule compositions for binding to hsp90
Structural differences in binding pockets of members of the HSP90 family can be exploited to achieve differential degradation of kinases and other signaling proteins through the use of designed small molecules which interact with the N-terminal binding pocket with an affinity which is greater than ADP and different from the ansamycin antibiotics for at least one species of the HSP90 family. Moreover, these small molecules can be designed to be soluble in aqueous media, thus providing a further advantage over the use of ansamycin antibiotics. Pharmaceutical compositions can be formulated containing a pharmaceutically acceptable carrier and a molecule that includes a binding moiety which binds to the N-terminal pocket of at least one member of the HSP90 family of proteins. Such binding moieties were found to have antiproliferative activity against tumor cells which are dependent on proteins requiring chaperones of the HSP90 family for their function. Different chemical species have different activity, however, allowing the selection of, for example Her2 degradation without degradation of Raf kinase. Thus, the binding moieties possess an inherent targeting capacity. In addition, the small molecules can be linked to targeting moieties to provide targeting of the activity to specific classes of cells. Thus, the invention further provides a method for treatment of diseases, including cancers, by administration of these compositions. Dimeric forms of the binding moieties may also be employed.
Owner:SLOAN KETTERING INST FOR CANCER RES
Novel VEGF mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
InactiveUS20130101628A1Improve biological activityCheap productionPeptide/protein ingredientsAntibody mimetics/scaffoldsPhosphorylationTherapeutic angiogenesis
Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro.
Owner:NORTHWESTERN UNIV
Multipartite signaling proteins and uses thereof
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
Owner:2SEVENTY BIO INC
Hybrid Ultrafast Laser Surgery and Growth Factor Stimulation for Ultra-Precision Surgery with Healing.
InactiveUS20100100084A1Promote healingInhibition formationPeptide/protein ingredientsSurgical drugsShock waveFemto second laser
The present invention relates to methods for laser surgery and growth factor stimulation for ultra-precision surgery with healing. The method is achieved by cutting biological tissue using an ultrafast laser, which produces laser pulses less than 10 picosecond in duration, to induce a cold ablation process in order to avoid the formation of carbonaceous or other materials that cannot be removed efficiently or completely from the wounded area through natural healing mechanisms. By use of femtosecond lasers, a negligible amount of debris is generated and an outer layer of intact but non viable cells are created principally through shock wave induce damage and ionizing radiation effects induced by multiphoton absorption of ultrashort laser pulses. The normal healing process is blocked by this outer layer of cells as all cell contacts are still intact. Therefore the healing process must be stimulated. The healing may be triggered or accelerated, or both, by application of growth factor molecules and / or signal proteins to the effectively undamaged cells causing the damaged cells to be replaced and the wound to close. The combination of very precise laser cutting used in combination with growth factors is the key to this unique tool.
Owner:GIRARD BRUNO +3
Methods to produce rod-derived cone viability factor (RDCVF)
The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
Owner:GENZYME CORP
A compound targeting ubiquitination to degrade Smad3
ActiveCN105085620BHas anti-fibrotic effectScientifically valuablePeptidesADAMTS ProteinsAnti fibrotic
The present invention provides a compound targeting ubiquitination degradation of Smad3, wherein the compound targeting ubiquitination degradation Smad3 is a compound represented by formula (I) and ubiquitin ligase E3 represented by formula (II) The recognition ligand is formed by linking the two through the Linker shown in formula (III). The present invention combines computer simulation screening and targeted ubiquitination degradation protein technology to construct a compound that can specifically bind to Smad3 and target degradation of Smad3 protein through the ubiquitination pathway, and confirms that it can target ubiquitination degradation Smad3 protein. Since Smad3 is the most important signal protein known to cause fibrosis, this Protac has anti-fibrosis effect theoretically, and because of its small molecular weight, it can freely enter and exit cells, and it is likely to become a new drug for the treatment of fibrosis, which not only has scientific value It also has important social value.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Use of the combination of semaphorin-4d inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
ActiveUS20130142810A1Immunoglobulins against growth factorsAntibody ingredientsTumor angiogenesisSEMA4D
Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF.
Owner:VACCINEX
Method for cell-free expression of signal protein and expression system
ActiveCN106011163ASolve the problem of low expressionHigh protein expressionNucleic acid vectorVector-based foreign material introductionEscherichia coliCreatine kinase
The invention relates to a method for cell-free expression of signal protein and an expression system. The method includes joining a target gene of the signal protein on a pIX3.0 vector to obtain expression plasmids; extracting escherichia coli Rosetta (DE3) by S30 buffer solution to obtain escherichia coli extract; preparing an energy supply system comprising PEP (phosphoenolpyruvic acid) / PK (pyruvate kinase), CP (phosphocreatine) / CK (creatine kinase) and glucose; preparing an amino acid mixture and a saline solution; preparing lecithin / cholesterol liposome; adding the expression plasmids into a cell-free protein expression system comprising the escherichia coli extract, the energy supply system, the amino acid mixture, the saline solution and the lecithin / cholesterol liposome for expression. The method is capable of solving the problem of small signal protein expression quantity.
Owner:CUSABIO TECH LLC
Multipartite signaling proteins and uses thereof
Owner:2SEVENTY BIO INC
MAVS in the prevention and treatment of viral diseases
InactiveUS20080003614A1High throughput screeningInhibitionBacteriaUnicellular algaeViral diseaseMitochondrial antiviral-signaling protein
The present invention includes compositions and methods for the identification, characterization and use of a novel anti-viral protein that includes a mitochondrial anti-viral signaling protein.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Combination detection reagent for detecting schistosomiasis and detecting method thereof
InactiveCN1700007AImprove standardizationEasy specificityTransferasesImmunoglobulinsAntigenGlutathione S-transferase
The invention relates to a combined medium and method for testing snail fever. It has the following characters: the medium contains recombination antigen mixture and recombination snail signal protein (rSj14-3-3) monoclonal antibody, and recombination antigen is mixed as recombination snail signal protein (rSj14-3-3) and recombination snail glutathione-s-transferase (rSjGST). The test operation is separately according to indirect enzyme immunosorbent test and double antibody bedded texture method. The invention adopts the two advantage diagnosis antigen molecule and its corresponding monoclonal antigen to form combined testing medium box.
Owner:ANHUI MEDICAL UNIV
Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1
ActiveUS20090087415A1Avoid delayShorten the progressOrganic active ingredientsBiocideBlood vesselNormal heart
It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule.
Owner:UT BATTELLE LLC
Composition for diagnosing, treating, and preventing liver disease
The present invention relates to a composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the said composition, a method for providing information necessary for diagnosing liver disease composed of the following steps; measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins.
Owner:SEOUL NAT UNIV R&DB FOUND
Superantibody synthesis and use in detection, prevention and treatment of disease
InactiveUS20120064593A1Improve toleranceReduce blockingImmunoglobulins against animals/humansEnzyme stabilisationPurineApoptosis
Superantibodies having enhanced autophilic, catalytic, and / or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and / or photoactivation. Autophilic superantibodies can promote apoptosis of target cells and / or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed.
Owner:INNEXUS BIOTECHNOLOGY INT LTD
Early Diagnosis and Novel Treatment of Cancer
InactiveUS20130216545A1Small sizeTreat cancerOrganic active ingredientsSugar derivativesSignalling pathwaysEphA Receptors
The present invention relates to novel therapies for treatment and new biomarkers for earlier detection of pancreatic and other cancers. In particular, the present invention identifies Reg1α and Reg3α, and other members of the Reg protein family, as signaling proteins for a receptor on the surface of human cancer cells, Megi, and the downstream pathways activated through this receptor in pancreatic and other tumor cells. These signaling proteins may be targeted by means known in the art to disrupt the downstream signaling pathway that catalyzes tumorigenesis, by the usage of antibodies, antisense, RNA interference, small molecule inhibitors and vaccines.
Owner:LEVETAN CLARESA
Neuronal cell lineages and methods of production thereof
InactiveUS20070053883A1Reduce concentrationBiocideOrganic active ingredientsNeural plateCyclodextrin
Methods are provided in which a sterol-depleting agent such as β-cyclodextrin (βCD), is used to modulate signaling by a differentiation signaling protein such as Hedgehog protein or a BMP in vitro. As illustrated herein, the use of βCD in conjunction with Sonic Hedgehog N-terminal peptide (ShhN) causes substantially all of the cells in neural plate explants to differentiate as neurons, such as motor neurons. Also provided are cell therapy methods and screening methods that rely on the modulation of signaling of a differentiation signaling protein such as Hedgehog, by a sterol-depleting agent such as βCD.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Reagents for the Detection of Protein Phosphorylation in Carcinoma Signaling Pathways
InactiveUS20110105732A1Immunoglobulins against cell receptors/antigens/surface-determinantsFermentationADAMTS ProteinsProtein phosphorylation
The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor / Scaffold proteins, Cytoskeleton proteins, GTP Signaling proteins, Kinases, Metabolism proteins, Phosphatases / Phospho-diesterases / Proteases, Receptor proteins, RNA Processing proteins, Transcription proteins, Translation proteins, Transporter proteins, and Ubitquitin proteins, as well as other protein types.
Owner:CELL SIGNALING TECHNOLOGY
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
InactiveUS20090099340A1Immunoglobulins against cell receptors/antigens/surface-determinantsFermentationADAMTS ProteinsProtein phosphorylation
The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor / Scaffold proteins, Cytoskeleton proteins, GTP Signaling proteins, Kinases, Metabolism proteins, Phosphatases / Phospho-diesterases / Proteases, Receptor proteins, RNA Processing proteins, Transcription proteins, Translation proteins, Transporter proteins, and Ubitquitin proteins, as well as other protein types.
Owner:CELL SIGNALING TECHNOLOGY
Genetically engineered bacterium for producing natamycin as well as construction method and application of genetically engineered bacterium
ActiveCN103923870AIncrease productionReduce manufacturing costBacteriaMicroorganism based processesEscherichia coliEngineered genetic
The invention discloses a genetically engineered bacterium for producing natamycin as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium is classified and named Streptomyces gilvosporeus and is collected with the serial number of CGMCC No.8901 in the China general microbiological culture collection center on march 7th, 2014. The construction method comprises the steps of constructing a recombinant plasmid by utilizing a cholesterol oxidase gene pimE; integrating the gene pimE into a Streptomyces gilvosporeus genome in an Escherichia coli and Streptomyces gilvosporeus conjugal transfer way; sieving to obtain a positive transconjugant. The genetically engineered bacterium can be used for increasing the density of pimE proteins in a fermentation liquid, and as signaling proteins, the pimE proteins can be used for improving the transcriptional level of a natamycin gene cluster and greatly increasing the fermentation yield of natamycin, so that the production cost is reduced, and huge social and economic benefits are brought.
Owner:SHANDONG UNIV +1
Identification of Biomarkers Predictive of Dasatinib Effects in Cancer Cells
InactiveUS20100004257A1Rapid correlationTreatment to begin more readilyOrganic active ingredientsDisease diagnosisSrc inhibitorCancer cell
A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents.
Owner:UNIV OF SOUTH FLORIDA
Generation of midbrain-specific organoids from human pluripotent stem cells
The present disclosure provides a method of deriving and maintaining a midbrain-like organoid in culture, comprising (a) culturing pluripotent stem cells to obtain neuronal lineage embryoid bodies; (b) culturing the neuronal lineage embryoid bodies from (a) to obtain midbrain regionalized tissues; (c) embedding and culturing the midbrain regionalized tissues from (b) in an extracellular matrix to obtain neuroepithelial tissues; and (c) culturing the neuroepithelial tissues from (c) to obtain a midbrain-like organoid. Also disclosed herein are culture media suitable for deriving and maintaining neuronal lineage embryoid bodies comprising (a) TGF-β Inhibitor and / or SMAD2 / 3 inhibitors; and (b) WNT-signaling activator; culture media suitable for deriving and maintaining midbrain regionalized tissues comprising (a) TGF-β Inhibitor and / or SMAD2 / 3 inhibitors; (b) WNT-signaling activator; (c) hedgehog signaling protein; and (d) fibroblast growth factor; culture media suitable for deriving and maintaining neuroepithelial tissues comprising (a) hedgehog signaling protein; and (b) fibroblast growth factor and culture media suitable for deriving and maintaining a midbrain-like organoid comprising (a) neurotrophin factor; (b) ascorbic acid; and (c) activator of cAMP-dependent pathway.
Owner:AGENCY FOR SCI TECH & RES +1
Application of integrin intracellular peptide sequences to inhibiting neovascularization
ActiveCN107253986AGrowth inhibitionCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsVaccinationConserved sequence
The invention relates to a series of peptide compounds containing integrin conserved sequences and having a function of inhibiting in vitro and vivo neovascularization. The functional peptide compounds have amino acid sequences shown as the first item of claims. The micromolecular peptide compounds can be coupled to cell-penetrating peptides to enter cells and then be combined with common signaling protein molecules to inhibit neovascularization and to achieve the effect of inhibiting in vivo solid tumor growth of tested mice. The peptide compounds belong to the field of biomedicine. The functional micromolecular peptide compounds and the effect protein molecules of the functional micromolecular peptide compounds can inhibit in vitro human umbilical vein endothelial cells from forming vascular structures, inhibit vascularization in subcutaneous vaccination matrix gels of nude mice and inhibit growth of subcutaneous vaccination solid tumors of the nude mice. The invention not only provides a number of leading compounds capable of inhibiting neovascularization, but also discloses a new neovascularization regulating mechanism, thereby providing new target sites for developing a new generation of neovascularization inhibiting and antineoplastic drugs.
Owner:SHANGHAI UNIV
Control of targeted turnover of key ethylene hormone signaling pathway proteins to modulate ethylene sensitivity in plants
Owner:ROHM & HAAS CO
Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1
ActiveUS8722625B2Avoid delayShorten the progressOrganic active ingredientsBiocideBlood vesselProtein C
It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule.
Owner:UT BATTELLE LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com